WEEKLY e-ALERT  [ BASIC EDITION ]
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
Update on Antitrust Legislative Development in China(11/15/2017 )  (Premium)
Competition Impact Review to Be Required for All New Chinese Regulations(11/15/2017 )  (Premium)
Ongoing Healthcare Reform in China(11/14/2017 )  (Premium)
U.S. Employs Rarely Used Tool to Probe China IP Practices(11/14/2017 )  (Premium)
The Market
McKinsey: Chinese Healthcare Market to Reach $1 Trillion by 2020(11/13/2017 )  (Premium)
Industry News
Listed Chinese Pharma Cos Remains Major Advertisers in H1/2017(11/19/2017 )  (Premium)
Domestically-listed Companies Maintains Growth in First 3Qs of 2017(11/19/2017 )  (Premium)
Shanghai Pharma Eyes Acquisitions in the U.S. and Europe Following Cardinal Deal(11/16/2017 )  (Premium)
Is Alliance Boots Pulling Out of Chinese JV Guangzhou Pharma(11/15/2017 )  (Premium)
Reckitt Benckiser, Alibaba Join Hands to Market Quality Health Products to China(11/14/2017 )  (free)
Shanghai Pharma Buys Cardinal Health's China Business for $1.2B(11/14/2017 )  (Premium)
XiAn Janssen Launches IMBRUVICA (ibrutinib) in China(11/13/2017 )  (Premium)
Pfizer Divests from Chinese JV with Hisun(11/13/2017 )  (Premium)
Regulatory News
CFDA Solicits Comments on Draft Amendment to the Rules for CFDA Legislation Procedures(11/17/2017 )  (Premium)
CFDA Solicits Public Comments on Provisions for Regulation of Internet Drug Business(11/14/2017 )  (Premium)
CFDA Issues New Announcement to Adjust Drug Registration Acceptance Rules(11/13/2017 )  (Premium)
CDE Seeks Comments on First List of Essential Drugs Eligible for BE Exemption and Simplified BE Studies(11/13/2017 )  (Premium)
General Health
CIRC Releases Draft Amendment of Health Insurance Regulation(11/16/2017 )  (Premium)
Fujian-led Inter-provincial Drug Purchase Alliance Imminent(11/15/2017 )  (Premium)
The National Cancer Center Joins Hands with WHO on the Fight against Cancer(11/13/2017 )  (Premium)
Legal/IPR News
China Issues New Measure to Ensure Fair Competition(11/15/2017 )  (Premium)
Product/R&D News
Ascentage Announces U.S. FDA Acceptance of Its IND for Novel IAP Inhibitor APG-1387(11/15/2017 )  (free)
RiboQuark Enrolls First Patient in China for a Global Pivotal Trial for siRNA Drug(11/13/2017 )  (Premium)
People in the News
Recent Official and Executive Moves(11/16/2017 )  (Premium)
Guo Guangchang to Resign Executive Posts at All Fosun Subsidiaries(11/13/2017 )  (Premium)
© Wicon International GroupˇˇSupport by: www.heightow.com Home | Site map | Contact Us | Links